Replies to post #454893 on Zeev's Turnips Patch-No Politics (ZEEV)

[zentman]

Putting GME on "toppy" watch. Looking for 45 SS. Nice round number, maybe next week.

[madrose1]

NitroMed to Present at Merrill Lynch Conference; February 8 at 11:00 AM ET
NitroMed Inc. (NASDAQ: NTMD) today announced that it will present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference, being held February 7 - 9 at the Grand Hyatt New York. Michael D. Loberg, Ph.D., NitroMed's President and Chief Executive Officer, will present a corporate overview and progress report on the commercial launch of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) on Wednesday, February 8, at 11:00 a.m. (ET).

The NitroMed presentation will be webcast live and may be accessed by visiting the Investor Relations section of the Company website (www.nitromed.com). The 40-minute presentation with question and answer session will be archived on the NitroMed website for a limited period of time following the conference.

About NitroMed, Inc.

NitroMed of Lexington, Massachusetts is a research-based emerging pharmaceutical company and the maker of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine available in the United States for the treatment of heart failure in self-identified black patients. In this population, BiDil is indicated as an adjunct to current standard therapies such as angiotensin converting enzyme (ACE) inhibitors and/or beta blockers. BiDil was approved by the U.S. Food and Drug Administration, primarily on the basis of efficacy data from the Company's landmark A-HeFT (African American Heart Failure Trial) clinical trial, and is marketed by NitroMed through a nationwide, dedicated sales force.

The Company is committed to the development of novel pharmaceuticals and safer, more effective versions of existing drugs to treat underserved patient populations. NitroMed's development efforts are primarily directed at expanding its cardiovascular franchise.

For full prescribing information, visit: www.BiDil.com. BiDil(R) is a registered trademark of NitroMed, Inc.


NitroMed, Inc.
Investor Relations
Sondra Newman, 781-266-4197
C: 781-640-3088
or
Media
Jane Kramer, 781-266-4220
C: 781-640-8499